Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Outlines Pricing Transparency Plan, Will Others Follow?

Executive Summary

CEO Gorsky describes J&J’s approach to drug pricing and pledges to provide more detail in an annual transparency report. Investor pressure regarding the pricing debate continued during the Novartis earnings call. Value arguments expected to dominate pharma’s message.


Related Content

Janssen's Drug Pricing Report Emphasizes Value Of Rebates
Janssen's Drug Pricing Report Emphasizes Value Of Rebates
Diabetes Rebate Model Challenged On Morality Grounds In Class Action Suit
J&J Promotes Preventive Care, Wellness In US Health Debate
US Drug Spending: Where Does All The Money Go?
Trump, Congress And The Search For Common Ground On Drug Pricing
Trump’s Drug Pricing Remarks: A Gambit For Industry Self-Restraint?
Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal
Novartis Woos Payers With Data Showing Entresto Earns Its Keep


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts